Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation20-05-2022
20-05-2022
Zydus Lifesciences Ltd - 532321 - Record For Payment Of Dividend Is July 29, 2022
Record for payment of dividend is July 29, 202220-05-2022
Zydus Lifesciences Ltd - 532321 - Record Date For Buy Back Of Shares Is June 2, 2022
Record date for Buy back of Shares is June 2, 202220-05-2022
Zydus Lifesciences Ltd - 532321 - Corporate Action-Board approves Dividend
Board approves the dividend20-05-2022
Q4FY22 Quarterly Result Announced for Zydus Lifesciences Ltd.
Pharmaceuticals firm Zydus Lifesciences declares Q4FY22 result: Quarterly Highlights: Revenue from operations at Rs. 38,638 mn, up 5% over last year. Research & Development (R&D;) investments for the quarter stood at Rs. 2,697 mn (7.0% of revenues). Reported EBITDA for the quarter was Rs. 7,177 mn; Reported EBITDA margin for the quarter stood at 18.6%. Adjusted for one-time inventory provision, EBIDTA margin stood at 22.3% of revenues. Reported Net Profit for the quarter was Rs. 3,974 mn. Adjusted for one-time inventory provision, exceptional and non-recurring items as well as profit from discontinued operations, Net Profit for the quarter was Rs. 5,250 mn, up 12% over last year. Capex (organic) for the quarter was Rs. 2,668 mn Yearly Highlights: Revenue from operations at Rs. 152,652 mn, up 6%. R&D; investments for the year were Rs. 10,406 mn (6.8% of revenues). Reported EBITDA for the year was Rs. 33,407 mn; Reported EBITDA margin for the year stood at 21.9%. Adjusted for one-time inventory provision, EBITDA margin stood at 23.1% of revenues. Reported net profit for the year was Rs. 44,873 mn, up 110%. Adjusted for one-time inventory provision, exceptional and non-recurring items as well as profit from discontinued operations, Net Profit for the year was Rs. 22,988 mn, up 12%. Capex (organic) for the year was Rs. 11,218 mn. Net Debt to Equity ratio as on 31st March, 2022 was ~ nil while Net Debt to EBITDA stood at -0.02x at the end of March, 2022. Net Cash (negative Net Debt) as on March 31, 2022 was Rs. 570 mn. Result PDF20-05-2022
Zydus Lifesciences Ltd - 532321 - Corporate Action-Intimation of Buy back
Intimation of Record Date20-05-2022
Zydus Lifesciences Ltd - 532321 - Board Meeting Outcome for Buy Back Of Shares
Buy Back of Shares20-05-2022
Zydus Lifesciences Ltd - 532321 - Annual Audited Financial Results For The Financial Year Ended On March 31, 2022
Annual Audited financial results for the financial year ended on March 31, 202220-05-2022
Zydus Lifesciences Ltd - 532321 - Board to consider Buyback of Equity Shares
With reference to the earlier letter dated May 13, 2022 intimating about the meeting of the Board of Directors of the Company scheduled to be held on May 20, 2022.Zydus Lifesciences Ltd has now informed BSE that the Board of Directors of the Company, at its aforesaid meeting, will also consider a proposal for buyback of fully paid-up equity shares of the Company and the matters necessary and incidental thereto, in accordance with the applicable provisions under the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws.17-05-2022